Nurix to work with Roche on BTK degrader Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 8 June, 2026

LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.

presented by De­liv­er­ing ex­cel­lence, close to home: Build­ing the in­fra­struc­ture for mod­ern com­mu­ni­ty on­col­o­gy

news Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal Nurix to work with Roche on BTK degrader in pact worth up to $2.3B Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal

The global one-stop conference convening experts across the drug discovery and development pipeline that will reshape the future of oncology therapeutics. sponsored by American Association for Cancer Research

#ADA26 Nearly 1 in 5 patients quit Boehringer and Zealand’s obesity shot over side effects Roche’s incretin shot works in mid-stage trial in type 1 diabetes Pfizer's good-enough obesity data in a crowded market may force competition on price, dosing Roche wants the best of both worlds with amylin-incretin combo strategy

Research Assistant (Chemistry) Arnatar San Diego, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it 1. In Washington, biotech's China hawks are winning the conversation 2. Industry seeks more clarity on commissioner's voucher program 3. House committee directs FDA to speed up IND sign-off process 4. Peer Review Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec 5. News Briefing Fulcrum lays off majority of staff; Seres extends runway into 2027 6. Innovent declares Phase 3 success for gastric cancer ADC that attracted huge Takeda deal 7. Pfizer-partnered obesity drugmaker eyes deals outside China 8. Your weight-loss drugs are next on the corporate chopping block